GSK's chronic hepatitis B therapy shows promise in key studies, analysts await full data

GSK will use promising results from two studies of its experimental chronic hepatitis B therapy to support planned regulatory ...
Fierce Biotech

GSK's 'functional cure' for hep B proves worth in phase 3 trials setting up approval push

GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, setting up the pharma for a push to the FDA.

Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepat…

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, ...
Infectious Disease Advisor

Bepirovirsen Meets Functional Cure Endpoint in Chronic Hepatitis B Trials

Topline data were announced from two phase 3 studies evaluating bepirovirsen for the treatment of chronic hepatitis B.
BioSpace

GSK, Ionis Achieve Functional Cure in Hepatitis B Studies, Clearing Path for FDA Run

Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.
European Medical Journal

End of lifelong pills? GSK’s phase 3 success in hepatitis B

GSK announced in January that its novel chronic hepatitis B (CHB) successfully met primary goals in two pivotal phase 3 ...
Clinical Trials Arena on MSN

GSK to file for approval of hep B drug on positive Phase III data

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.
Los Angeles Times

Hepatitis B: Understanding the Virus, Symptoms, and Global Prevention Efforts

Hepatitis B is a serious liver disease caused by the hepatitis B virus (HBV), which is a small DNA virus from the Hepadnaviridae family. If someone has this infection for a long time, it can lead to ...
NPR

Hepatitis B: What parents should know about the virus and the vaccine

For more than three decades, it has been routine to give all newborns in the U.S. the hepatitis B vaccine. That could soon change. An advisory committee to the Centers for Disease Control and ...